文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

三阴性乳腺癌全身治疗的进展

Advances in systemic therapies for triple negative breast cancer.
PubMed 文献 · BMJ · 2023-05-30

本综述聚焦三阴性乳腺癌(TNBC)的现代管理,重点讨论可手术患者全身治疗的最新进展,包括术前免疫治疗获批后的实践挑战与未解问题,并概述转移性TNBC治疗领域的最新 promising 进展及未来方向。

要点

  • 可手术TNBC的治疗策略转向术前全身治疗升级,并根据术后反应调整后续方案。
  • 肿瘤生物学进步识别出特定分子特征亚群,推动了多种靶向治疗在该病中的测试与获批。
  • 抗体药物偶联物的进展正在重新定义乳腺癌的分类方案。

核心结论

  • TNBC仍是复发率和死亡率最高的乳腺癌亚型。
  • 可手术TNBC的治疗重点包括全身治疗升级和向术前给药转变,并采用基于术后反应调整的辅助全身治疗策略。
  • 对肿瘤生物学的深入理解已识别出具有特定分子特征的患者亚群,促使多种新靶向治疗在该病中获批。
  • 抗体药物偶联物的进展正在重新定义乳腺癌的分类方案。

研究设计与样本

  • 本文为综述,聚焦TNBC的现代管理,重点讨论可手术疾病治疗的最新更新,并概述转移性疾病治疗领域的最新 promising 进展。

主要发现

  • TNBC缺乏雌激素受体表达和HER2扩增,数十年来依赖细胞毒性化疗。
  • 可手术TNBC中,改善结局的努力集中于全身治疗升级及向术前给药转变,随后根据反应调整术后全身治疗。
  • 肿瘤生物学进步识别出特定分子特征亚群,促成多种新靶向治疗的测试与获批。
  • 抗体药物偶联物的进展正在重新定义乳腺癌分类方案。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 原文讨论了新辅助免疫治疗获批带来的实践挑战和未解问题,并分享了在证据缺乏领域的临床处理方式。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. The lack of expression of targetable proteins such as the estrogen receptor and absence of HER2 amplification have made relying on cytotoxic chemotherapy necessary for decades. In the operable setting, efforts to improve outcomes have focused on escalation of systemic therapy and a shift toward preoperative delivery followed by a response adapted approach to postoperative systemic therapy. An improved understanding of tumor biology has resulted in the identification of subsets of patients with specific molecular features, leading to testing and approval of multiple new targeted therapies for this disease. Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that are redefining classification schemes for breast cancer. This review focuses on the modern management of TNBC, with particular focus on recent updates in the treatment of operable disease, and an overview of the most recent promising advances in the therapeutic landscape of metastatic disease. It discusses the practical challenges and unanswered questions resulting from the approval of neoadjuvant immunotherapy and shares an approach in the clinic on topics for which evidence is lacking. In addition, it provides a glimpse into the future, highlighting challenges and opportunities for biomarker based right-sizing of preoperative therapy, refining evaluation of response to preoperative therapy after surgery, early diagnosis and detection of relapse, and areas of needed research for metastatic TNBC.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023. PMID: 37253507. doi:10.1136/bmj-2022-071674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。